Drug intelligence / Profile preview

Mangoral

Development stage: Phase 3
Lead developer: Ascelia Pharma
Modality: Small Molecules
Administration: Oral

Overview

Mangoral is an oral diagnostic agent developed by Ascelia Pharma AB, currently in Phase 3 clinical development. It is designed to improve the detection and visualization of focal liver lesions, including liver metastases and primary tumors, in patients with severe renal impairment who are at risk of serious side effects from gadolinium-based contrast agents. Mangoral is a combination drug containing manganese chloride tetrahydrate, L-alanine, and vitamin D3. Its primary mechanism involves manganese acting as an MRI contrast agent to enhance image quality.

Brand names: Orviglance
Other names: Mangoral

Beyond the preview

Go deeper on Mangoral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mangoral.

Explore the full profile